Sensitivity test of anticancer agents by subrenal capsule assay (SRC assay) . II--Determination of tumor sensitivity by percentage inhibition of DNA protein
Nishiyama, M.; Noso, Y.; Yamaguchi, M.; Hirabayashi, N.; Toge, T.; Niimoto, M.; Hattori, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(2): 275-279
1986
ISSN/ISBN: 0385-0684 PMID: 3080963 Document Number: 279886
Subrenal capsule assay(SRC assay) has been reported to be an effective and rapid method for predicting the tumor sensitivity of individual patients to anti-cancer agents. In order to establish a more objective method of determining sensitivity in SRC assay the DNA content was measured by the schmidt-Thannhauser-Schneider method and the protein content was estimated using Bio-Rad protein assay, after removal of a tumor implanted in the subrenal capsular space of ddY mice. Percentage inhibition of DNA/protein had a high correlation with that of relative increase of tumor weight, although three groups treated with mitomycin-C, 5-fluorouracil and cyclophosphamide indicated different values of tumor sensitivity. From these results, the percentage inhibition of DNA/protein seems to be more objective than microscopic measurement for predicting tumor sensitivity.